Top

Published in:

01-04-2021 | Colchicine | Case Based Review

COVID-19 in patients with familial Mediterranean fever treated with colchicine: case based review

Authors: Kemal Nas, Nuran Eryilmaz, Mehmet Faruk Geyik, Ayfer Altaş

Published in: Rheumatology International | Issue 4/2021

Abstract

Coronavirus disease 2019 (COVID-19) refers to the clinical picture of an important and severe infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Considering the current knowledge on the pathophysiology and clinical manifestations of COVID-19, it is safe to state that both COVID-19 and inflammatory rheumatic disorders cause a cytokine storm and merit treatment with anti-rheumatic drugs. Three patients, who were on regular follow-up due to the diagnosis of familial Mediterranean fever (FMF), contracted COVID-19 infection; and their pre-clinical and post-clinical data as well as laboratory, prognosis and treatment data were investigated. Effects of colchicine in FMF patients who contracted COVID-19 infection were presented in this study. All the cases recovered from COVID-19 without complications. The present study suggests that colchicine can positively affect the prognosis of COVID-19 in FMF patients; therefore, experience of rheumatologists in the use of anti-inflammatory drugs can be highly instrumental in management of COVID-19 patients.

Caso F, Costa L, Ruscitti P, Navarini L, Del Puente A, Giacomelli R, Scarpa R (2020) Could sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? Autoimmun Rev 19(5):102524–102524. https://doi.org/10.1016/j.autrev.2020.102524CrossRefPubMedPubMedCentral

Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426(6965):450–454. https://doi.org/10.1038/nature02145CrossRefPubMedPubMedCentral

Pope RM, Tschopp J (2007) The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthritis Rheum 56(10):3183–3188. https://doi.org/10.1002/art.22938CrossRefPubMed

Cacoub PP (2014) Colchicine for treatment of acute or recurrent pericarditis. Lancet 383(9936):2193–2194. https://doi.org/10.1016/S0140-6736(14)60113-6CrossRefPubMed

Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, Knossow M (2004) Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 428(6979):198–202. https://doi.org/10.1038/nature02393CrossRefPubMed

Deftereos SG, Siasos G, Giannopoulos G, Vrachatis DA, Angelidis C, Giotaki SG, Gargalianos P, Giamarellou H, Gogos C, Daikos G, Lazanas M, Lagiou P, Saroglou G, Sipsas N, Tsiodras S, Chatzigeorgiou D, Moussas N, Kotanidou A, Koulouris N, Oikonomou E, Kaoukis A, Kossyvakis C, Raisakis K, Fountoulaki K, Comis M, Tsiachris D, Sarri E, Theodorakis A, Martinez-Dolz L, Sanz-Sánchez J, Reimers B, Stefanini GG, Cleman M, Filippou D, Olympios CD, Pyrgakis VN, Goudevenos J, Hahalis G, Kolettis TM, Iliodromitis E, Tousoulis D, Stefanadis C (2020) The Greek study in the effects of colchicine in COVID-19 complications prevention (GRECCO-19 study): rationale and study design. Hellenic J Cardiol 61(1):42–45. https://doi.org/10.1016/j.hjc.2020.03.002CrossRefPubMedPubMedCentral

Hentgen V, Vinit C, Fayand A, Georgin-Lavialle S (2020) The use of interleukine-1 inhibitors in familial mediterranean fever patients: a narrative review. Front Immunol 11:971–971. https://doi.org/10.3389/fimmu.2020.00971CrossRefPubMedPubMedCentral

Chen IY, Moriyama M, Chang M-F, Ichinohe T (2019) Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. Front Microbiol 10:50–50. https://doi.org/10.3389/fmicb.2019.00050CrossRefPubMedPubMedCentral

Nerlekar N, Beale A, Harper RW (2014) Colchicine–a short history of an ancient drug. Med J Aust 201(11):687–688. https://doi.org/10.5694/mja14.00846CrossRefPubMed

10.

Vitiello A, Ferrara F, Pelliccia C, Granata G, Porta RL (2020) Cytokine storm and colchicine potential role fighting SARS-CoV-2 pneumonia. ITJM. https://doi.org/10.4081/itjm.2020.1284CrossRef

11.

Grailer JJ, Canning BA, Kalbitz M, Haggadone MD, Dhond RM, Andjelkovic AV, Zetoune FS, Ward PA (2014) Critical role for the NLRP3 inflammasome during acute lung injury. J Immunol 192(12):5974–5983. https://doi.org/10.4049/jimmunol.1400368CrossRefPubMed

12.

Nieto-Torres JL, Verdiá-Báguena C, Jimenez-Guardeño JM, Regla-Nava JA, Castaño-Rodriguez C, Fernandez-Delgado R, Torres J, Aguilella VM, Enjuanes L (2015) Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome. Virology 485:330–339. https://doi.org/10.1016/j.virol.2015.08.010CrossRefPubMed

13.

Misra DP, Agarwal V, Gasparyan AY, Zimba O (2020) Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. ClinRheumatol 39(7):2055–2062. https://doi.org/10.1007/s10067-020-05073-9CrossRef

14.

Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C (2020) Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 79(5):667–668. https://doi.org/10.1136/annrheumdis-2020-217424CrossRefPubMed

15.

Kobak S (2020) COVID-19 infection in a patient with FMF: does colchicine have a protective effect? Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217882CrossRefPubMed

16.

Haslak F, Yildiz M, Adrovic A, Sahin S, Koker O, Aliyeva A, Barut K, Kasapcopur O (2020) Management of childhood-onset autoinflammatory diseases during the COVID-19 pandemic. RheumatolInt 40(9):1423–1431. https://doi.org/10.1007/s00296-020-04645-xCrossRef

17.

Mansouri N, Marjani M, Tabarsi P, von Garnier C, Mansouri D (2020) Successful treatment of covid-19 associated cytokine release syndrome with colchicine. A case report and review of literature. Immunol Invest. https://doi.org/10.1080/08820139.2020.1789655CrossRefPubMedPubMedCentral

18.

Hausmann JS (2019) Targeting cytokines to treat autoinflammatory diseases. ClinImmunol 206:23–32. https://doi.org/10.1016/j.clim.2018.10.016CrossRef

19.

Molad Y (2002) Update on colchicine and its mechanism of action. CurrRheumatol Rep 4(3):252–256. https://doi.org/10.1007/s11926-002-0073-2CrossRef

20.

Bourguiba R, Delplanque M, Vinit C, Ackermann F, Savey L, Grateau G, Hentgen V, Georgin-Lavialle S (2020) Clinical course of COVID-19 in a cohort of 342 familial mediterranean fever patients with a long-term treatment by colchicine in a French endemic area. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-218707CrossRefPubMed

21.

El Hasbani G, Jawad A, Uthman I (2019) Update on the management of colchicine resistant familial mediterranean fever (FMF). Orphanet J Rare Dis 14(1):224–224. https://doi.org/10.1186/s13023-019-1201-7CrossRefPubMedPubMedCentral

22.

Filocamo G, Mangioni D, Tagliabue P, Aliberti S, Costantino G, Minoia F, Bandera A (2020) Use of anakinra in severe COVID-19: a case report. Int J Infect Dis 96:607–609. https://doi.org/10.1016/j.ijid.2020.05.026CrossRefPubMedPubMedCentral

23.

Pontali E, Volpi S, Antonucci G, Castellaneta M, Buzzi D, Tricerri F, Angelelli A, Caorsi R, Feasi M, Calautti F, Castagnola E, Rollandi GA, Ravelli A, Cassola G, Gattorno M (2020) Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. J Allergy ClinImmunol 146(1):213–215. https://doi.org/10.1016/j.jaci.2020.05.002CrossRef

24.

Aouba A, Baldolli A, Geffray L, Verdon R, Bergot E, Martin-Silva N, Justet A (2020) Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. Ann Rheum Dis 79(10):1381–1382. https://doi.org/10.1136/annrheumdis-2020-217706CrossRefPubMed

Title: COVID-19 in patients with familial Mediterranean fever treated with colchicine: case based review
Authors: Kemal Nas
Nuran Eryilmaz
Mehmet Faruk Geyik
Ayfer Altaş
Publication date: 01-04-2021
Publisher: Springer Berlin Heidelberg
Keywords: Colchicine
SARS-CoV-2
COVID-19
Cytokines
Familial Mediterranean Fever
Published in: Rheumatology International / Issue 4/2021
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-021-04809-3

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2021

Association of systemic lupus erythematosus with hearing loss: a systemic review and meta-analysis

Occupational mimics of rheumatoid arthritis: hair dye-induced arthritis

Improving the quality of life of patients with rheumatoid arthritis after rehabilitation irrespective of the level of disease activity

The impact of COVID-19 on rheumatology patients in a large UK centre using an innovative data collection technique: prevalence and effect of social shielding

Aortic involvement in relapsing polychondritis: case-based review

COVID-19 outcomes in patients with familial Mediterranean fever: a retrospective cohort study

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage